Urology Medical News about Testicular cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Testicular cancer: RPLND an effective first-line alternative to chemotherapy
NCP Urology, 06/11/09

Payton S - Men with nonseminomatous germ cell tumors (NSGCTs) who are at high risk of metastasis can benefit from retroperitoneal lymph node dissection (RPLND) as primary treatment. The recent development of safer dissection techniques that reduce the risk of retrograde ejaculation add to its potential as a first-line treatment in testicular cancer. Long-term complications linked to cisplatin-based treatment include cardiovascular disease and metabolic syndrome. Secondary malignancy associated with radiation exposure during post-chemotherapy follow-up CT imaging would also be avoided by employing this management strategy.